3351-53-9 Usage
General Description
2-bromoethyl 3,4-dimethylphenyl ether is a synthetic chemical compound which falls under the class of organic compounds known as aryl-alkyl ethers. These are ethers with the general formula R1-O-R2 where R1 or R2 is an aryl group. It specifically features a bromoethyl group bound to an ether functional group, and a phenyl ring substituted with two methyl groups at positions 3 and 4. The molecular structure of this compound can also exhibit aromatic characteristics. As a laboratory reagent, it is typically used in specific chemical synthesis or reactions due to its chemical properties. Despite these potential uses, it is essential to handle this compound with care due to potential hazards associated with it. The specific properties, applications and hazards of this chemical can further be identified through additional detailed information or data.
Check Digit Verification of cas no
The CAS Registry Mumber 3351-53-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,3,5 and 1 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 3351-53:
(6*3)+(5*3)+(4*5)+(3*1)+(2*5)+(1*3)=69
69 % 10 = 9
So 3351-53-9 is a valid CAS Registry Number.
InChI:InChI=1/C10H13BrO/c1-8-3-4-10(7-9(8)2)12-6-5-11/h3-4,7H,5-6H2,1-2H3
3351-53-9Relevant articles and documents
Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I)
Guo, Xiaoke,Ma, Xianglei,Yang, Qian,Xu, Jing,Huang, Lu,Jia, Jianmin,Shan, Jiaojiao,Liu, Li,Chen, Weilin,Chu, Hongxi,Wei, Jinlian,Zhang, Xiaojin,Sun, Haopeng,Tang, Yiqun,You, Qidong
supporting information, p. 89 - 94 (2014/06/09)
Kv1.5 potassium channel is an efficacious and safe therapeutic target for the treatment of atrial fibrillation (AF), the most common arrhythmia that threatens human. Herein, by modifying the hit compound 7k from an in-house database, 48 derivatives were synthesized for the assay of their Kv1.5 inhibitory effects by whole cell patch clamp technique. Six compounds which showed better potency than the positive compound dronedarone were selected for the next evaluation of their drug-like properties. Compound 8 exhibited balanced solubility and permeability. It also showed acceptable pharmacodynamics profile with very low acute toxicity. Taking all these data into account, compound 8 can serve as a promising lead for the development of novel therapeutic agent for the treatment of AF.
MONOAMINE OXIDASE INHIBITORS. THE SYNTHESIS AND EVALUATION OF A SERIES
DRAIN,HOWES,LAZARE,SALAMAN,SHADBOLT,WILLIAMS
, p. 63 - 69 (2007/10/05)
-
